Core Insights - Traditional Chinese medicine company Shouxiangu (603896) is diversifying into fast-moving consumer goods (FMCG) due to performance challenges, hiring former Wahaha sales manager Shen Jiangang to oversee operations [1][2] - The company has established a multi-category matrix for food and medicine integration, launching products like Dendrobium juice and Shouxiangu porridge, with all FMCG operations managed by its subsidiary [1][2] Financial Performance - Since its listing in May 2017, Shouxiangu's revenue grew continuously for six years, peaking at 829 million yuan in 2022, but saw a 5.39% decline in 2023 to 784 million yuan, with a further 11.81% drop projected for 2024 [2] - The company's net profit followed a similar trend, experiencing an 8.39% decline in 2023 and a projected 31.34% drop in 2024 [2] Recent Quarterly Results - In the first half of 2023, Shouxiangu reported total revenue of 300 million yuan, down 16.51% year-on-year, and a net profit of approximately 65.56 million yuan, down 33.99% [5] - The second quarter showed improvement with revenue of 129 million yuan, a decline of 6.64%, compared to a 22.68% drop in the first quarter, with July showing positive growth [5] Product Performance - In the first half of 2023, revenue from Ganoderma lucidum spore products was 216 million yuan, accounting for 73.11% of total revenue, down 17.79% year-on-year [5] - Revenue from Dendrobium products was 46.66 million yuan, representing 15.83% of total revenue, down 24.25% [6] Strategic Direction - Shouxiangu aims to maintain its focus on high-end products like third-generation broken-wall Ganoderma lucidum spore powder while considering a mix of high, medium, and low-tier products for different channels [7] - The company acknowledges the current market challenges and emphasizes the importance of effectively reaching consumers to capitalize on untapped market potential [8]

Group 1 - The board of directors of Zhejiang Shouxiangu Pharmaceutical Co., Ltd. held its fourth meeting of the fifth session on October 14, 2025, with all nine directors present, confirming compliance with relevant laws and regulations [1] - The board approved the election of Li Mingyan as the executive director and legal representative of the company, with a term lasting until the end of the fifth board session, with a unanimous vote of 9 in favor [1] - The board confirmed the members and convener of the audit committee, which will now assume the responsibilities previously held by the supervisory board, with Jin Ying as the convener, also serving until the end of the fifth board session [1]

Group 1 - The fifth meeting of the fifth board of directors of Zhejiang Shouxiangu Pharmaceutical Co., Ltd. was held on October 14, 2025, with all nine directors present [2] - The board approved the election of Li Mingyan as the executive director and legal representative of the company, effective immediately [3] - The board confirmed the members and convener of the audit committee, with Jin Ying as the convener, and decided to abolish the supervisory board [5]

| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2025-065 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 | 转债 22 | | 浙江寿仙谷医药股份有限公司 第五届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江寿仙谷医药股份有限公司（以下简称"公司"）第五届董事会第四次会 议于 2025 年 10 月 14 日在公司会议室以现场结合通讯表决方式召开，会议通知 于 2025 年 10 月 10 日以电子邮件形式发出，会议应到董事 9 名，实到董事 9 名， 公司高级管理人员、董事会秘书、证券事务代表列席了会议。本次会议由董事长 李明焱先生主持，会议的召开符合《公司法》及《公司章程》的有关规定。 根据《中华人民共和国公司法》《上市公司章程指引》及《公司章程》的规 定，董事会同意选举李明焱先生为代表公司执行事务的董事，并担任公司法定代 表人，任期自本次董事会审议通过之日起至第五届董事会届满之日止。 ...

Group 1 - The core point of the article is that Shouxiangu (SH 603896) held its fourth meeting of the fifth board of directors on October 14, 2025, to review various proposals, including the confirmation of the audit committee members and the convener [1] - For the first half of 2025, Shouxiangu's revenue composition was as follows: manufacturing accounted for 95.69%, other businesses for 2.67%, and additional business activities for 1.63% [1] - As of the time of reporting, Shouxiangu's market capitalization was 4.1 billion yuan [1]

| 债券代码：113660 | 债券简称：寿 转债 | | --- | --- | | | 22 | | 证券代码：603896 | 证券简称：寿仙谷 公告编号：2025-064 | 根据《上海证券交易所股票上市规则》等有关法律法规的规定和《浙江寿仙 谷医药股份有限公司公开发行可转换公司债券募集说明书》的约定，"寿 22 转债" 转股期自 2023 年 5 月 23 日至 2028 年 11 月 16 日止（如遇法定节假日或休息日延 至其后的第 1 个工作日；顺延期间付息款项不另计息）。"寿 22 转债"的初始转 股价格为 38.08 元/股；因实施公司 2022 年度权益分派，"寿 22 转债"转股价格 自 2023 年 7 月 4 日由 38.08 元/股调整为 37.65 元/股；因实施公司 2023 年度权益 分派，"寿 22 转债"转股价格自 2024 年 6 月 20 日由 37.65 元/股调整为 37.27 元 /股；因公司发生回购专用证券账户股份注销相关事宜，自 2024 年 7 月 8 日，"寿 22 转债"转股价格由 37.27 元/股调整为 37.11 元/股；因实施公司 2024 年 ...

Investment Rating - The industry investment rating is maintained at "Overweight" [2] Core Viewpoints - The initiation of the real-world comprehensive value evaluation pilot work by the National Medical Insurance Administration is expected to enhance the clinical evaluation system for traditional Chinese medicine (TCM) [8][9][10] - The TCM sector has shown a relative performance decline compared to the broader pharmaceutical sector, with a 1.95% drop last week [4][14] - The TCM sector's current Price-to-Earnings (PE) ratio is 27.38X, reflecting a slight decrease, while the Price-to-Book (PB) ratio stands at 2.32X [6] Market Performance - The TCM index closed at 6449.62 points, down 1.95% last week, while the overall pharmaceutical sector fell by 2.2% [4][14] - The performance of individual companies within the TCM sector varied, with notable gainers including Fangsheng Pharmaceutical and Tianmu Pharmaceutical, while companies like Zhongsheng Pharmaceutical and Zhendong Pharmaceutical lagged [5][20][22] Valuation Metrics - The TCM sector's PE (ttm) is at 27.38X, down 0.54X week-on-week, with a one-year range of 24.72X to 30.26X [6] - The PB (lf) is recorded at 2.32X, also showing a slight decrease, with a one-year range of 2.17X to 2.65X [6] Supply Chain Insights - The demand for TCM materials has increased, particularly for gift-giving purposes, leading to a slight rise in the price index [7] - The overall price index for TCM materials was 237.22 points, reflecting a 0.4% increase from the previous week [7] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [11][12] - Specific investment targets include companies with strong R&D capabilities and unique products, as well as those less affected by centralized procurement [11][12]

Core Viewpoint - The company has successfully completed the re-registration of its "Shouxiangu Brand Ganoderma Spore Oil Soft Capsules," ensuring stable production and sales, while aiming for product transformation and upgrading in the traditional Chinese medicine sector [1][14]. Group 1: Company Performance - From 2017 to 2022, the company's total revenue increased from 370 million to 829 million, with net profit rising from 89 million to 278 million [3]. - However, in 2024, the company experienced a revenue decline of 11.81% to 692 million and a net profit drop of 31.34% to 175 million [3][6]. - In the first half of 2025, the company reported a revenue of 300 million, down 16.51%, and a net profit of 66 million, down 33.99% [10]. Group 2: Product Structure and Strategy - The sales revenue from Ganoderma spore powder products accounted for 70.87%, 69.27%, and 65.75% of the company's main business income from 2022 to 2024, indicating a reliance on a single product line [1]. - The company is focusing on diversifying its product offerings while maintaining its core business, with plans to enhance research and development of rare traditional Chinese medicinal materials [1][2]. - The company has initiated marketing reforms and established a national distributor system to improve sales performance [11]. Group 3: Market Outlook - The company anticipates that Ganoderma spore powder could become the leading product in the health supplement market, surpassing other products like Cordyceps and bird's nest [7]. - The company aims to reach a scale of 10 billion by 2035, despite recent setbacks in growth [7].

Core Points - Zhejiang Shouxiangu Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Jinhua Shouxiangu Pharmaceutical Co., Ltd., has completed the re-registration of its health food product, "Shouxiangu Brand Ganoderma Spore Oil Soft Capsules," and received the registration certificate from the State Administration for Market Regulation [1][2][3] - The successful re-registration ensures the normal production and sales of the product, playing a crucial role in stabilizing the company's product system [1] - The company will continue to adhere to its established plans, focusing on its core business, leveraging existing industry advantages, and targeting cutting-edge technology in traditional Chinese medicine [1] - The company aims to conduct in-depth research and development on precious traditional Chinese medicinal materials such as Ganoderma, Dendrobium, and Saffron, to achieve product transformation and upgrade, thereby strengthening its core business [1]

Core Viewpoint - The company emphasizes its commitment to innovation and product efficacy enhancement across the entire industry chain, focusing on traditional and modern practices in its operations [1] Group 1: Product Innovation - The company has developed a unique wall-breaking technology that removes the shell of Ganoderma lucidum spore powder, resulting in over tenfold increases in the content of effective components [1] - The absorption rates of different effective components have improved by 4 to 50 times due to this new technology [1] Group 2: Research and Development - The company is conducting research on the combination of wall-broken Ganoderma lucidum spore powder with anti-tumor drugs, with some results already published in academic papers [1]